Oryzon Genomics SA (ORY)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 2.510 |
|---|---|
| 52-week range | 2.480 – 3.745 |
| Return, 1 month / 3 months | −8.1% / −15.9% |
| Return, 1 year / 3 years | −24.4% / +24.0% |
| Trend | Below its 200-day average |
| RSI (14) | 35 |
| Volatility (1 year) | 33.2% |
| Worst drawdown (1 year) | -29.4% |
| Average daily value traded | 0.41M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Oryzon Genomics is a clinical-stage biopharmaceutical company based in Spain that works on epigenetics-based medicines. It develops small-molecule drugs that target epigenetic enzymes, with programmes in oncology and in disorders of the central nervous system. Its pipeline includes compounds studied in blood cancers and in neurodegenerative and neurodevelopmental conditions. The company carries out its own research and clinical development and works with partners and academic groups to advance its drug candidates through testing.
The shares are listed on the Madrid Stock Exchange in Spain under the code ORY, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Oryzon Genomics SA (ORY) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 2.510 on 27 October 2026.
Its price-based Market X-Ray is 32 out of 100 (a weak price profile), ranking 192 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.4% and over the last three months it fell 15.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -13.6% | ||
| From 52-week high | -29.1% | ||
| Momentum | 21 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -15.9% | ||
| 6-month return | -10.7% | ||
| 12-month return, skipping the last month | -17.7% | ||
| Stability (higher is calmer) | 29 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 33.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.4% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 0.41M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −2.7% |
|---|---|
| 1 month | −8.1% |
| 3 months | −15.9% |
| 6 months | −10.7% |
| 1 year | −24.4% |
| 3 years | +24.0% |
| 5 years | −17.4% |
Signals
| 50-day / 200-day average | 2.722 / 2.904 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.066 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.